Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $91.6 million.

  • Relay Therapeutics' Cash & Equivalents fell 39.90% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year decrease of 39.90%. This contributed to the annual value of $124.3 million for FY2024, which is 13.53% down from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Cash & Equivalents is $91.6 million, which was down 19.64% from $113.9 million recorded in Q2 2025.
  • Relay Therapeutics' Cash & Equivalents' 5-year high stood at $354.6 million during Q3 2022, with a 5-year trough of $91.6 million in Q3 2025.
  • Its 3-year average for Cash & Equivalents is $133.2 million, with a median of $143.7 million in 2023.
  • Data for Relay Therapeutics' Cash & Equivalents shows a peak YoY increase of 273.49% (in 2021) and a maximum YoY decrease of 59.13% (in 2021) over the last 5 years.
  • Relay Therapeutics' Cash & Equivalents (Quarterly) stood at $280.1 million in 2021, then tumbled by 45.81% to $151.8 million in 2022, then declined by 5.31% to $143.7 million in 2023, then dropped by 13.53% to $124.3 million in 2024, then tumbled by 39.90% to $91.6 million in 2025.
  • Its Cash & Equivalents stands at $91.6 million for Q3 2025, versus $113.9 million for Q2 2025 and $93.5 million for Q1 2025.